Skip to content
Menu

Evolus, Inc. EOLS

Full chart Compare
Set alert

Price alert · EOLS

All alert types
7.00 USD -0.07 (-0.99%)

Regular-session close

7.00 0.00 0.00%

After hours · Nov 19, 4:01 PM ET

6.93 Day range 7.21
3.86 52-week range 9.31
YTD
+5.26%
1 year
+3.24%

5D -0.17 (-2.48%)

6.5077.50WedThuFriMonTue6.69
Market cap
463.32M
Revenue (ttm)
248.33M
Profit margin
-22.33%
EPS (ttm)
-0.48
Shares out
63.32M
Forward P/E
54.20
YTD return
+5.26%
1-year return
+3.24%
50-day average
14.00
Volume
870.98K
Avg volume
918.91K
Open
7.03
Previous close
7.07
Day's range
6.93 – 7.21
52-week range
3.86 – 9.31
Beta
1.31
Analysts
Buy
Price target
23.43 (+234.7%)

Key statistics

200-day average
13.56
Enterprise value
734.41M
Price / sales
2.76
Price / book
116.56
Revenue growth
22.10%
Free cash flow
-7.40M
Total cash
85.03M
Total debt
129.88M
Short % of float
8.41%

Fundamental scorecard

7 of 25 checks passed on EOLS’s reported financials

ValueGrowthProfitabilityHealthDividend

7of 25 checks passed

  • Value 1 of 5
  • Growth 3 of 5
  • Profitability 1 of 5
  • Financial health 2 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
EOLS Revenue — quarterly 77.95M
EOLS Net income — quarterly -12.52M
EOLS EPS — quarterly -0.19

Earnings

EOLS recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 6, 2024Sep 1, 2024-0.08-0.19-0.11-137.50%
Jul 31, 2024Jun 1, 2024-0.04-0.07-0.03-75.00%
Jul 31, 2024Jun 1, 2024-0.04———
May 7, 2024Mar 1, 2024-0.07-0.13-0.06-85.71%
May 7, 2024Mar 1, 2024-0.07———
Mar 7, 2024Dec 1, 2023-0.07———

Upgrades / downgrades

EOLS analyst upgrades and downgrades
DateFirmActionFromTo
Nov 7, 2024HC Wainwright & Co.reitBuyBuy
Nov 1, 2024HC Wainwright & Co.reitBuyBuy
Oct 3, 2024HC Wainwright & Co.reitBuyBuy
Sep 16, 2024Cantor Fitzgeraldreit—Overweight
Sep 13, 2024BarclaysmainOverweightOverweight
Sep 13, 2024NeedhamreitBuyBuy

About Evolus, Inc.

Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Nuceiva, for the temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at maximum frown. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
United States
Website
evolus.com

News

Your note

Sign in to keep a note on EOLS — it syncs with the Stock Master app.

Insider holders

EOLS insider holders
InsiderRelationLatest transactionDateShares held
AVELAR RUI L.OfficerSaleMay 9, 2024368,847
BEAVER SANDRAChief Financial OfficerSaleSep 5, 2024148,502
BLANK SIMONEDirectorStock Award(Grant)Feb 6, 2024552,530
GILL DAVID N.DirectorSaleMay 13, 202433,964
HAYMAN ROBERTDirectorStock Award(Grant)Feb 6, 202465,222
MALIK VIKRAMDirectorSaleJun 2, 2024246,514

Institution ownership

EOLS institution ownership
Holder% heldSharesValueReported
Perceptive Advisors Llc8.46%5,356,62258.07MSep 29, 2024
Tang Capital Management, LLC7.66%4,847,39952.55MSep 29, 2024
Blackrock Inc.6.68%4,230,14945.85MSep 29, 2024
Vanguard Group Inc5.05%3,195,33134.64MSep 29, 2024
Nantahala Capital Management, LLC4.46%2,824,84930.62MSep 29, 2024
Caligan Partners, LP3.46%2,193,48823.78MSep 29, 2024

Fund ownership

EOLS fund ownership
Holder% heldSharesValueReported
Vanguard Total Stock Market Index Fund2.66%1,684,16718.26MSep 29, 2024
iShares Russell 2000 ETF2.25%1,422,21415.42MOct 30, 2024
Vanguard Extended Market Index Fund1.12%708,6337.68MSep 29, 2024
Fidelity Small Cap Index Fund0.89%564,7946.12MAug 30, 2024
Oberweis Micro-Cap Portfolio0.81%514,9005.58MSep 29, 2024
iShares Russell 2000 Growth ETF0.78%492,5175.34MOct 30, 2024